ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.91
-2.51 (-24.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.42
Open7.95
Bid7.95 x 900
Ask8.00 x 400
Day's Range7.43 - 8.13
52 Week Range5.42 - 19.15
Volume4,000,881
Avg. Volume267,168
Market Cap107.271M
Beta4.88
PE Ratio (TTM)N/A
EPS (TTM)-2.79
Earnings DateAug 9, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.17
Trade prices are not sourced from all markets
  • Main Line synthetic cannabinoid developer seeking $32.5M from stock sale
    American City Business Journals12 hours ago

    Main Line synthetic cannabinoid developer seeking $32.5M from stock sale

    The proceeds will be used to advance then company's experimental treatment for Fragile X Syndrome.

  • Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks
    MarketWatch13 hours ago

    Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks

    Valuations today are very high and sentiment is very positive — a bad combination, says Nigam Arora.

  • GlobeNewswire15 hours ago

    Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Zynerba Pharmaceuticals, Inc. (ZYNE) today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share, for a gross deal size of $32.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Zynerba has granted the underwriters a 30-day option to purchase up to 609,375 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Cantor Fitzgerald & Co. is acting as the sole book-running manager.

  • Benzinga17 hours ago

    Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 19) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Champions Oncology ...

  • GlobeNewswireyesterday

    Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Zynerba Pharmaceuticals, Inc. (ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be offered by Zynerba.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Zynerba intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. Cantor Fitzgerald & Co. is acting as the sole book-running manager.

  • GlobeNewswire9 days ago

    Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome

    -Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002-- Presentation Today at the 16 th NFXF International Fragile X Conference-. ...

  • GlobeNewswire12 days ago

    Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome

    DEVON, Pa., July 09, 2018 (GLOBE NEWSWIRE) --  Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the initiation of a multi-national, randomized, double blind placebo controlled Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X (CONNECT-FX). The CONNECT-FX trial will evaluate the efficacy and safety of ZYN002 (CBD Gel) in children ages three to 17 with full mutation Fragile X syndrome (FXS). FXS is a genetic condition that causes intellectual disability, behavioral and learning challenges and is the most common known single gene cause of autism spectrum disorder.

  • MarketWatch13 days ago

    Zynerba stock rebounds after selloff driven by failed cannabis-based skin patch trial

    Shares of Zynerba Pharmaceuticals Inc. rose 7% in Friday trade, recouping some of their prior-session losses that came after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals. Zynerba(ZYNE) , which is developing cannabis-based therapies for rare neurospsychiatric disorders, said the trial of ZYN001, which delivers tetrahydrocannabinol (THC) through a transdermal patch, did not achieve its goal of target blood levels of 5 to 14 ng/ml THC in healthy volunteers. THC is the psychoactive ingredient in cannabis and the company was trying to find a way to deliver it without patients having to take it orally, which can make them high.

  • Benzinga15 days ago

    HC Wainwright Unfazed By Zynerba Ending ZYN001: Drug 'Wasn't In Our Numbers'

    Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) stock plummeted 17.8 percent at Thursday’s open after the company ended a Phase 1 study for ZYN001, a tetrahydrocannabinol patch. While there were no adverse ...

  • Benzinga16 days ago

    Zynerba Redirects Resources After ZYN001 Study Fails To Meet Top-Line Results

    Although the pro-drug of tetrahydrocannabinol was “very well tolerated” by the skin and no adverse events were reported, Zynerba is terminating the study. It will instead focus its time and resources on ZYN002 for Fragile X syndrome, developmental and epileptic encephalopathy and adult refractory epilepsy. ZYN002 will begin a pivotal study of ZYN002 in Fragile X in “mid-year 2018” and continue Phase 2 trials for the other two indications.

  • MarketWatch16 days ago

    Zynerba shares slide 17% after trial of cannabis-based skin patch fails to meet goals

    Shares of Zynerba Pharmaceuticals Inc. (zyne) slid about 17% in premarket trade Thursday, after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals. The company, which is developing cannabis-based therapies for rare neruospsychiatric disorders, said the trial of ZYN001, a patent-protected, pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch, in healthy volunteers, did not achieve its goal of target blood levels of 5 to 14 ng/ml THC. "This Phase 1 study was a single and multiple dose, placebo-controlled first-in-man study to assess the safety and pharmacokinetics of ZYN001 administered as a transdermal patch to healthy adult subjects," Zynerba said in a statement.

  • GlobeNewswire16 days ago

    Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced top line results from a Phase 1 clinical program studying ZYN001, the Company’s patent-protected, pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch, in healthy volunteers. As a result of these data, the Company will focus its development efforts and investments on the ZYN002 Fragile X syndrome, developmental and epileptic encephalopathy (DEE) and adult refractory epilepsy programs. The Company expects that this change will extend its cash runway into the second half of 2019.

  • TheStreet.com24 days ago

    FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

    approaching the U.S launch of its long-awaited Epidiolex epilepsy medicine, the space for cannabis-based drugs to treat the disorder and other maladies is finally moving into reality. London-based GW Pharma said Monday (June 25) the U.S. Food and Drug Administration (FDA) has approved Epidiolex, a cannabinoid-based oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome -- both rare forms of epilepsy -- in patients at least two years old.

  • Benzinga25 days ago

    GW Pharma's Epidiolex Becomes First Cannabis-Based FDA-Approved Drug

    The drug is derived from the cannabidiol of cannabis, and, as the plant is yet to be decriminalized by federal regulators, its approval gives GW Pharma a lead among cannabis-exposed companies in the U.S. financial markets. The FDA seal is nonetheless seen to be a boon for the broader industry. “It makes it harder for Congress to continue to list cannabis as a Schedule I controlled substance,” Debra Borchardt, CEO at cannabis-focused financial media outlet Green Market Report, told Benzinga in April.

  • GlobeNewswire2 months ago

    Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the Jefferies 2018 Global Healthcare Conference on Thursday June 7, 2018 at 10:30 AM EDT at the Grand Hyatt hotel in New York, NY. Zynerba Pharmaceuticals (ZYNE) is a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders with high unmet medical needs.

  • The Tech Revolutionizing The Billion Dollar Marijuana Business
    Oilprice.com2 months ago

    The Tech Revolutionizing The Billion Dollar Marijuana Business

    Reefer madness is reaching a full-blown frenzy, with total legal worldwide marijuana sales expected to surpass $63 billion in less than ten years. And now the tech behind bitcoin is poised to take the cannabis boom to the next level

  • Investopedia2 months ago

    Pot Stock Winners of the Week

    Here are the week's four biggest marijuana stock winners.

  • Interested In Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? Here’s How It Performed Recently
    Simply Wall St.2 months ago

    Interested In Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? Here’s How It Performed Recently

    Understanding how Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense checkRead More...

  • Associated Press2 months ago

    Zynerba: 1Q Earnings Snapshot

    The Devon, Pennsylvania-based company said it had a loss of 91 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights

    DEVON, Pa., May 08, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...

  • GlobeNewswire3 months ago

    Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)

    Continued Improvement in Seizure Control Seen in Adult Refractory Focal Seizure Patients Receiving ZYN002 through 12 Months of Open Label Exposure. LOS ANGELES, April 25, 2018-- Zynerba Pharmaceuticals, ...

  • GlobeNewswire3 months ago

    Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018

    Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced an oral presentation to be given at the16th NFXF (National Fragile X Foundation) International Fragile X Conference. The oral presentation will describe data from the FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study that highlight the short- and long-term positive impact of ZYN002 on children and adolescents with Fragile X syndrome (FXS). Zynerba is committed to supporting the needs of patients, their families and health care practitioners, and to developing this novel therapy to treat the behavioral symptoms associated with Fragile X syndrome as expeditiously as possible,” said Dr. Liza Squires, Zynerba’s Chief Medical Officer.

  • What Do Analysts Think About Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) Earnings Trend?
    Simply Wall St.3 months ago

    What Do Analysts Think About Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) Earnings Trend?

    The most recent earnings announcement Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) released in December 2017 confirmed that losses became smaller relative to the prrior year’s level as a result of recent tailwindsRead More...

  • Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes
    Investor's Business Daily3 months ago

    Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes

    GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.